The University of Southampton
University of Southampton Institutional Repository

Biosynthesis of cysteinyl-leucotrienes in aspirin-intolerant asthma

Biosynthesis of cysteinyl-leucotrienes in aspirin-intolerant asthma
Biosynthesis of cysteinyl-leucotrienes in aspirin-intolerant asthma
Most medical concern over the worldwide use of aspirin (acetylsalicylic acid), the leading over-the-counter analgesic in many countries, has focused on the rare occurrences of Reye's syndrome (encephalopathy with hepatic failure) and gastric erosion in patients taking large aspirin doses for rheumatoid arthritis. Hypersensitivity to aspirin manifested as severe respiratory dysfunction has been relatively disregarded. Adverse respiratory reactions to aspirin and other non-steroidal anti-inflammatory drugs (NSAID) are well documented in the literature, but frequently overlooked in asthmatic patients. Only 3–5% of adult asthmatics have a clinical history of NSAID hypersensitivity, but this rises to about 20% when asthmatics are challenged with NSAIDs in the laboratory.

Aspirin-intolerant asthma (AIA) is a syndrome with features reminiscent of a protracted viral respiratory infection. Classic symptoms of chronic rhinoconjunctivitis, nasal polyps and bronchial asthma typically define the syndrome [ 1]. The onset of AIA is insidious, with a peak incidence around 35 years of age, although AIA has been observed in adolescents. AIA usually persists for life, but in some cases the disease is self-limiting. In AIA patients, acute hypersensitivity reactions to NSAIDs are superimposed upon a background of chronic, severe asthma. Acute asthma attacks may be precipitated following ingestion of even small doses of aspirin (frequently less than 80 mg), often accompanied by congestion of the conjunctiva and nasal mucosa. AIA patients usually have adverse reactions to a wide range of NSAIDs. Bronchoconstriction may be severe and life-threatening, requiring hospital admission and sometimes mechanical ventilation. Up to 25% of hospital admissions for acute asthma requiring emergency mechanical ventilation may be caused by NSAID ingestion. Aspirin and other NSAIDs must be avoided by AIA patients, although the atypical NSAID paracetamol and the new cyclooxygenase-2-selective NSAIDs (e.g. meloxicam) may be better tolerated. Even in the absence of exposure to NSAIDs, the underlying severity of chronic asthma necessitates oral corticosteroid therapy in 50% of AIA patients. Desensitization, in which incremental oral doses of aspirin extinguish adverse reactions as long as the drug is regularly ingested, may alleviate clinical symptoms, especially rhinosinusitis. This review will discuss the evidence for a fundamental abnormality in cysteinyl-leukotriene synthesis in AIA patients, which provides a rationale for the clinical use of leucotriene modifier (LM) drugs in these patients.
0954-7894
306-313
Sanak, M.
e6bbd98c-9d96-4146-9347-ac9d128b69ab
Sampson, A. P.
4ca76f6f-ff35-425d-a7e7-c2bd2ea2df60
Sanak, M.
e6bbd98c-9d96-4146-9347-ac9d128b69ab
Sampson, A. P.
4ca76f6f-ff35-425d-a7e7-c2bd2ea2df60

Sanak, M. and Sampson, A. P. (1999) Biosynthesis of cysteinyl-leucotrienes in aspirin-intolerant asthma. Clinical and Experimental Allergy, 29 (3), 306-313. (doi:10.1046/j.1365-2222.1999.00443.x).

Record type: Review

Abstract

Most medical concern over the worldwide use of aspirin (acetylsalicylic acid), the leading over-the-counter analgesic in many countries, has focused on the rare occurrences of Reye's syndrome (encephalopathy with hepatic failure) and gastric erosion in patients taking large aspirin doses for rheumatoid arthritis. Hypersensitivity to aspirin manifested as severe respiratory dysfunction has been relatively disregarded. Adverse respiratory reactions to aspirin and other non-steroidal anti-inflammatory drugs (NSAID) are well documented in the literature, but frequently overlooked in asthmatic patients. Only 3–5% of adult asthmatics have a clinical history of NSAID hypersensitivity, but this rises to about 20% when asthmatics are challenged with NSAIDs in the laboratory.

Aspirin-intolerant asthma (AIA) is a syndrome with features reminiscent of a protracted viral respiratory infection. Classic symptoms of chronic rhinoconjunctivitis, nasal polyps and bronchial asthma typically define the syndrome [ 1]. The onset of AIA is insidious, with a peak incidence around 35 years of age, although AIA has been observed in adolescents. AIA usually persists for life, but in some cases the disease is self-limiting. In AIA patients, acute hypersensitivity reactions to NSAIDs are superimposed upon a background of chronic, severe asthma. Acute asthma attacks may be precipitated following ingestion of even small doses of aspirin (frequently less than 80 mg), often accompanied by congestion of the conjunctiva and nasal mucosa. AIA patients usually have adverse reactions to a wide range of NSAIDs. Bronchoconstriction may be severe and life-threatening, requiring hospital admission and sometimes mechanical ventilation. Up to 25% of hospital admissions for acute asthma requiring emergency mechanical ventilation may be caused by NSAID ingestion. Aspirin and other NSAIDs must be avoided by AIA patients, although the atypical NSAID paracetamol and the new cyclooxygenase-2-selective NSAIDs (e.g. meloxicam) may be better tolerated. Even in the absence of exposure to NSAIDs, the underlying severity of chronic asthma necessitates oral corticosteroid therapy in 50% of AIA patients. Desensitization, in which incremental oral doses of aspirin extinguish adverse reactions as long as the drug is regularly ingested, may alleviate clinical symptoms, especially rhinosinusitis. This review will discuss the evidence for a fundamental abnormality in cysteinyl-leukotriene synthesis in AIA patients, which provides a rationale for the clinical use of leucotriene modifier (LM) drugs in these patients.

This record has no associated files available for download.

More information

Published date: 1999
Additional Information: Copyright: Copyright 2007 Elsevier B.V., All rights reserved.

Identifiers

Local EPrints ID: 455198
URI: http://eprints.soton.ac.uk/id/eprint/455198
ISSN: 0954-7894
PURE UUID: 28fab6b5-c183-40b2-aa2f-08a15278201f
ORCID for A. P. Sampson: ORCID iD orcid.org/0009-0008-9653-8935

Catalogue record

Date deposited: 15 Mar 2022 17:33
Last modified: 17 Mar 2024 02:43

Export record

Altmetrics

Contributors

Author: M. Sanak
Author: A. P. Sampson ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×